Title of article :
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Author/Authors :
Nick Thatcher، نويسنده , , Alex Chang، نويسنده , , Purvish Parikh، نويسنده , , Jose Rodrigues Pereira، نويسنده , , Tudor Ciuleanu، نويسنده , , Joachim von Pawel، نويسنده , , Sumitra Thongprasert، نويسنده , , Eng Huat Tan، نويسنده , , Kristine Pemberton، نويسنده , , Venice Archer، نويسنده , , Kevin Carroll، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2006
Pages :
11
From page :
1527
To page :
1537
Abstract :
Background This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer. Methods 1692 patients who were refract
Journal title :
The Lancet
Serial Year :
2006
Journal title :
The Lancet
Record number :
588859
Link To Document :
بازگشت